SEARCH:   Advanced

Blood, 1 October 2007, Vol. 110, No. 7, pp. 2316-2323. Prepublished online as a Blood First Edition Paper on June 20, 2007; DOI 10.1182/blood-2007-02-074641. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-02-074641v1 110/7/2316    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gallamini, A. Articles by Tarella, C. Search for Related Content PubMed PubMed Citation Articles by Gallamini, A. Articles by Tarella, C. Related Collections Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Andrea Gallamini1, Francesco Zaja2, Caterina Patti3, Atto Billio4, Maria Rosaria Specchia5, Alessandra Tucci6, Alessandro Levis7, Annunziata Manna8, Vicenzo Secondo9, Luigi Rigacci10, Antonello Pinto11, Emilio Iannitto12, Valerio Zoli13, Pierfederico Torchio14, Stefano Pileri15, and Corrado Tarella16 1 Hematology Department, Ospedale Santa Croce, Cuneo; 2 Hematology Department, Università di Udine, Udine; 3 Hematology Department, Ospedale Cervello, Palermo, Sicily; 4 Hematology Department, Ospedale Regionale Generale, Bolzano; 5 Hematology Department, Ospedale Santa Giuseppe Moscati, Taranto; 6 Hematology Department, Ospedale Spedali Civili, Brescia; 7 Hematology Department, Ospedale Santa Antonio e Biagio, Alessandria; 8 Onco-Hematology Department, Ospedale Azienda Sanitaria Locale 5, La Spezia; 9 Internal Medicine Department, Ospedale Galliera, Genova; 10 Hematology Department, Università di Firenze, Firenze; 11 Onco-Hematology Department, Ospedale Pascale, Napoli; 12 Hematology Department, Università di Palermo, Palermo, Sicily; 13 Hematology Department, Ospedale Santa Camillo Forlanini, Roma; 14 Medical Statistics Department, Università di Torino, Torino; 15 Hemolymphopathology Department, Università di Bologna, Bologna; 16 Hematology Department, Università di Torino, Torino, Italy To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day –1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follow-up of 16 months (range, 5-42 months), 14 patients were alive, 9 had died from progressive disease, and 1 had died from pneumonia at day +198 while in CR. So far, 13 are disease-free, with an overall median duration of response of 11 months. The most frequent side effects were grade 4 neutropenia and cytomegalovirus (CMV) reactivation. Major infections were Jacob-Creutzfeldt (J-C) virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis, and pneumonia. This study shows that CHOP-C: (1) is a feasible chemoimmunotherapy regimen; (2) is effective in PTCL with a high rate of CR achievement; and (3) is associated with mostly manageable infectious complications. This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID no. 141202. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. C. Kluin-Nelemans, J. L. Coenen, J. E. Boers, G. W. van Imhoff, and S. Rosati EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma Blood, August 15, 2008; 112(4): 1039 - 1041. [Abstract] [Full Text] [PDF] G. Jaeger, F. Bauer, R. Brezinschek, C. Beham-Schmid, C. Mannhalter, and P. Neumeister Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine Ann. Onc., May 1, 2008; 19(5): 1025 - 1026. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020